The effects of propranolol and corticosterone on susceptibility priming in a mouse model of social defeat stress Authors: Alessia Manganaro, Jack Yin Zhang, Giulia Zanni, Clementine Fillinger, Dani Dumitriu Published: 2026 ABSTRACT AbstractAnimal models for stress-related mood disorders aim to mirror the diverse spectrum of stress responses observed in humans, which ultimately determine an individual’s susceptibility or capacity to cope effectively with the stressor. The acute social defeat stress (ASDS) protocol allows a rapid phenotypic classification of mice subjected to social stress to interrogate the early neural patterns beyond divergent stress outcomes. Although ASDS alone does not cause chronic depression-like behaviors, it “primes” the mouse to be highly susceptible to a subsequent, subthreshold stress (StSDS). Here, we tested whether pharmacological manipulation shortly before ASDS can counter this susceptibility priming. Specifically, we examined the β-adrenergic receptor antagonist propranolol and the glucocorticoid corticosterone. Male mice received acute intraperitoneal injections of propranolol, corticosterone, or saline prior to ASDS, followed one week later by StSDS and social interaction testing. Propranolol partially prevented the emergence of social avoidance following subsequent StSDS, without modifying the behavioral outcome of ASDS. In contrast, corticosterone administered at different doses, failed to prevent susceptibility priming to later StSDS, disrupting also the typical acute ASDS behavioral profiling at low and medium doses. The results suggest that blocking β-adrenergic signaling during an acute stressor can reduce future stress susceptibility, while underscoring the complex and dose-dependent effects of glucocorticoids on stress responsivity.Subject terms: Biomarkers, Learning and memory Introduction Chronic stressors are more likely to lead to psychopathology than single stressful events [1]. In humans, cumulative stress has been shown to increase the prevalence of several physical and mental health conditions, including hypertension, substance abuse disorders, and depression in susceptible individuals [1–3]. Evidence suggests that exposure to an initial stressor potentiates risk of subsequently developing psychopathology after additional stressors by “priming” stress circuits. This has been dubbed the two-hit hypothesis [4]. It suggests that complex diseases such as schizophrenia and depression are the result of two or more major disruptions during critical periods — the first increasing the risk of pathogenesis, while the second triggering actual disease onset. Both disturbances are necessary to induce the disorder, but neither alone is sufficient [4, 5]. A possible mechanism by which this priming effect manifests is the process of memory consolidation [6–8]. Whereas the complex mechanisms by which stress impacts memory have not yet been fully characterized, growing evidence supports an important role played by stress hormones and their targets [6, 9, 10], which are investigated in the treatment of post-traumatic stress disorder (PTSD) both in animal models and humans [11–13]. One compound targeting the stress response pathway is the beta-adrenergic receptor antagonist, propranolol. Across rodent studies, propranolol administration diminished fear response following reactivation of the learned fear memory [14–16]. Comparable effects have been demonstrated in humans as well, with Vaiva et al. reporting lower rates of PTSD in patients prescribed propranolol post-trauma compared to those who did not [17]. A second compound of interest is cortisol in humans, or its counterpart, corticosterone, in rodents. Several studies reported patients with PTSD have lower cortisol levels [12, 18]. A single high-dose corticosteroid injection in the acute aftermath of a traumatic event has gained some traction as a post-exposure prophylaxis to supplement a diminished stress response [11, 13, 19]. In rats exposed to a predator scent, high-dose corticosterone reduced the prevalence of extreme behavioral disruption 30 days later [20]. A similar impairment in fear memory was reported in mice infused with corticosterone following foot shock conditioning [21]. To investigate the potential of propranolol and corticosterone in preventing susceptibility priming to social stress by an initial stressful event on a future repeat stressor, we utilized the social defeat stress (SDS) paradigm, a commonly used animal model of stress-induced depressive-like behavior [22]. During SDS, mice undergo physical aggression from a larger conspecific that causes in a proportion of mice physiological and social deficits, including alterations to various neurotransmitter systems and metabolic disturbances [22]. In the present study, we used the acute social defeat stress (ASDS) and subthreshold social defeat stress (StSDS) models. The ASDS model, established in our lab to investigate pre-existing neurocircuitry differences underlying individual variability in stress responses, induces quantifiable differences in social avoidance between control and defeat animals, without inducing long-term pervasive depressive-like behaviors [23]. The StSDS model usually fails to induce significant social avoidance in defeated animals [22, 24]. However, we previously observed that mice subjected to StSDS after having experienced ASDS are primed to exhibit social avoidance [22]. Here, we investigated whether acute administration of either propranolol or corticosterone, preceding an acute stress priming event, is capable of mitigating or inhibiting susceptibility priming to a subsequent subthreshold stressor in male mice. Materials and methods Animals We used 8-week-old male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) and retired male breeder CD-1 mice (Charles River Laboratory, Wilmington, MA). All mice were housed in a temperature-controlled room under 12-h diurnal conditions (light phase: 08:00–20:00 EST). Mice were group-housed four per cage in standard microisolator cages with wood-chip bedding. Food and water were provided ad libitum. The male CD-1 mice were retired breeders under 4-months age, and single-housed in a room separate from the experimental mice. The aggressor animals were screened before the experiment, according to the protocol by Golden et al. [22]. Briefly, non-experimental naïve C57BL/6J mice are used as intruder to the CD1 cages for 4–5 days, and the latency and number of attacks for each CD1 used to score the aggression level. The aggressive CD1 Trio selected and the sequence of encounters for each mouse are randomized. CD1 mice that show a reduction in aggression along the experiment are replaced with new aggressive ones as described in Golden et al. [22]. Non-aggressive CD-1 mice were used as the novel social target during the social interaction test. All animals used in this study were maintained in accordance with the recommendations of the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. All experiments were performed in strict adherence with the protocol approved by the Institutional Animal Care and Use Committee at the Icahn School of Medicine at Mount Sinai, New York Psychiatric Institute and Columbia University. The number of animals used was based on power analysis using preliminary lab data. Drugs and preparation Across the experiments, all compounds were administered intraperitoneally (i.p.). Propranolol hydrochloride (West-Ward Pharmaceuticals, cat. 0143-9872-10) (PROP) was administered at a dose of 10 mg/kg. The corticosterone (CORT) solution was prepared from ≥98.5% powdered corticosterone (Sigma-Aldrich, Cat. 50-22-6), ethanol, and corn oil. We used three doses: 0.1 mg/kg (low), 5 mg/kg (medium), and 25 mg/kg (high). The appropriate amount of CORT was prepared by first suspending the powder in 0.5 mL of ethanol. This suspension was then vortexed and sonicated at 37 °C, until dissolved. 4.5 mL of corn oil was then added to the mixture, vortexed, and sonicated. Solutions were prepared fresh on the experimental day and kept in the sonicator at 37 °C until injection. The drug/vehicle solutions were injected in a volume of 1 ml/kg body weight. Social defeat stress (SDS) Behavioral testing was conducted between 12:00 and 16:00. Animals underwent ASDS, followed by StSDS one week later (Fig. 1A). Experimental design of the Propranolol and Corticosterone experiments. A Experimental Timeline B Schematic representation of the two consecutive trials of SIT, without and with target (non-aggressive CD1) in the interactor. The “interaction zone” and the “corners zone” are depicted in green and red respectively. C Examples of mean occupancy heatmaps for two mice showing social approach and avoidant behavior respectively during the SIT Target session. Both protocols are adaptations of the resident-intruder paradigm described by Golden et al. [22] and previously published by our lab 23. The ASDS protocol consisted of three consecutive rounds of two-minute defeat sessions with three different CD-1 aggressors, followed by 54 min of single housing in a clean cage prior to social interaction testing (SIT). In the StSDS, animals similarly underwent three 5-min rounds of defeat with different aggressors, with 15-min rest intervals in their home cages in-between. Following the third defeat round, StSDS mice returned to their home cages and SIT conducted 24 h later. The ASDS control group underwent a controlled social interaction (CI) with a new non-aggressive C57 mouse during three encounters. Mice with a history of ASDS underwent defeat sessions in the subsequent StSDS. Social interaction test (SIT) Following ASDS and StSDS, SIT was tested at one hour and 24 h respectively, under red light conditions as previously described [22, 23]. SIT quantifies social preference versus avoidance (Fig. 1C). Experimental mice were placed into an opaque Plexiglas open-field arena (42 × 42 × 42 cm) with a rectangular wire-mesh enclosure placed against one of the inner walls. Experimental animals explored the arena for 150 sec with “no target” present in the enclosure for habituation and baseline activity monitoring (Fig. 1A & B). The animals were then removed, the arena cleaned with 70% ethanol, and a novel non-aggressive CD1 “target” mouse placed into the enclosure as the social target. Experimental animals returned to the arena for another 150 sec. Video-tracking (EthoVision 10 software, Noldus Information Technology) was used to record behavior. Total time spent in the “interaction zone”, an unmarked rectangular region around the interaction enclosure (14 × 24 cm); and “corners zone” (9 × 9 cm, cumulative two corners on the opposite wall from the enclosure) were quantified. Social Interaction (SI) and corner ratios were calculated by dividing time spent in the zones during “target” by time during “no target” (Fig. 1B & C) [22–24]. Exp. 1: Effect of propranolol on susceptibility priming The experiment was conducted over the course of nine days (Fig. 1A), with four groups of randomly assigned animals: animals injected with saline and subjected to CI (SAL_CTR, n = 12); animals injected with saline and subjected to ASDS (SAL_DEF, n = 19); animals injected with propranolol and subjected to CI (PROP_CTR, n = 12); and animals injected with propranolol and subjected to ASDS (PROP_DEF, n = 16). On the first day, animals underwent ASDS, followed by SIT one hour later (Fig. 1A). Thirty minutes before ASDS, animals were injected with either saline or propranolol according to body weight and returned in their group-housed home cage. Defeat group animals underwent ASDS (SAL_DEF; PROP_DEF), while control group animals underwent CI (SAL_CTR; PROP_CTR). Animals were placed in clean individual cages until SIT and returned with their prior cage mates after it. StSDS occurred 1-week later (Fig. 1A). All animals underwent subthreshold defeat, regardless of group assignment during the ASDS. No drug was administered during the StSDS. Animals were returned to their original home cage and housing room. SIT was repeated 24 h after StSDS. The effects of propranolol injected 2 min after ASDS was tested in both control and defeated groups (SAL_CTR, n = 3; PROP_CTR, n = 6; SAL_DEF, n = 3; PROP_DEF, n = 6) (Figure S2D). Exp. 2: Effect of corticosterone on susceptibility priming Animals underwent a similar experimental design as those in Exp. 1 (Fig. 1A). 40 animals were randomly assigned to six different groups: animals receiving the lowest dose of corticosterone (0.1 mg/kg) and CI (LOW_CTR, n = 6); animals receiving the lowest dose of corticosterone and ASDS (LOW_DEF, n = 6); animals receiving the medium dose of corticosterone (5 mg/kg) and CI (MED_CTR, n = 7); animals receiving the medium dose of corticosterone and ASDS (MED_DEF, n = 7); animals receiving the highest dose of corticosterone (25 mg/kg) and CI (HI_CTR, n = 7); and animals receiving the highest dose of corticosterone and ASDS (HI_DEF, n = 7). All animals underwent defeat in the StSDS paradigm one week following ASDS, regardless of group assignment during ASDS (Fig. 1A). The effects of the medium dose of corticosterone (5 mg/kg) or vehicle injected 2 min after ASDS was also tested (VEH_DEF, n = 3; MED_DEF, n = 6; VEH_CTR, n = 3; MED_CTR, n = 6) (Fig. 4E). Serum corticosterone profiles ASDS social avoidance outcomes without altering post-ASDS susceptibility priming. A Bar graph of the absolute time animals spent in the interaction zone (IZ) during SIT following ASDS, in the no target and target sessions. B Bar graph of the time the animals spent exploring the corners zone (CZ) during SIT after ASDS, in the no target and target sessions. C SI ratios in control (CTR) and defeated (DEF) groups following ASDS. D Serum CORT levels across different time points for VEH CTR, MED CTR (superimposed) and VEH DEF and MED DEF (superimposed). E Experimental timeline of the post ASDS corticosterone injection experiment on the left. Violin dot plot graph shows SI ratios in control (CTR) and defeated (DEF) groups following ASDS and StSDS in corticosterone (MED CORT) and vehicle (VEHICLE) groups. Dashed line denotes the threshold for social avoidance (SI ratio = 1). Data are presented as mean +/− SEM. Post-hoc: *P < 0.05, **P < 0.01. Corticosterone time course Corticosterone serum levels were measured at different time points in mice randomly assigned to be injected with vehicle or medium dose of corticosterone 30 min before CI or ASDS (VEH_DEF, n = 6; MED_DEF, n = 6; VEH_CTR, n = 4; MED_CTR, n = 4). We collected tail blood two days and one day prior to ASDS to establish a baseline. On the day of the experiment, we collected tail blood at 15, 30, 65, and 120 min after ASDS. SIT was performed 60 min after ASDS initiation, between the 30-min and the 65-min blood collection time points. Blood was collected in tubes containing heparin (Microvette®100 K3E, EDTA Preparation, Sarstedt) and maintained on ice. Samples were centrifuged at 4000 rpm for 15 min and serum collected. We quantify CORT serum levels with the ELISA kit (Enzo Biochem Inc., ADI-900-097). Serum samples were diluted at 1:40 as directed by manufacture instructions. Statistics We used repeated mixed effect model and two-way repeated measures ANOVA, followed by a Šídák’s or Tukey’s post-hoc multiple comparisons test as recommended, to compare the difference between each pair of group means (CTR_vs_DEF, and SAL_vs_PROP/CORT) and within pair (ASDS_vs_StSDS). Statistical significance was defined as p < 0.05. For serum CORT levels, data were analyzed by fitting a mixed model, followed by a Dunnett’s post-hoc multiple comparisons test as recommended. All statistical analyses were conducted in Graphpad Prism 11. Investigators were blinded to the group allocation during the analysis. Results Propranolol reduces ASDS-induced stress-priming to subsequent StSDS We previously showed that ASDS robustly induces social avoidance on SIT one-hour post-defeat [23]. Although not resulting in persistent social avoidance, ASDS primes to subsequent social stress, including StSDS paradigm that would not otherwise lead to susceptibility under control conditions [23]. We hypothesized that this priming is mediated by consolidation of the initial stress memory and that disrupting consolidation immediately after ASDS would prevent priming to subsequent stressor. To test whether propranolol blocks ASDS-induced stress-priming, mice underwent ASDS in the presence or absence of propranolol (PROP_vs_SAL), followed by StSDS one week later. Mice received propranolol or saline injections 30 min before ASDS and tested for social avoidance versus social preference using standard SIT testing one hour after initiation of ASDS (Fig. 1A & 2A). Because here we were interested in the effects of the animal’s history (stress-priming and/or drug treatment) on subsequent susceptibility, all mice, irrespective of drug treatment, further underwent defeat in StSDS, and no drug or saline was administered at time of StSDS. Propranolol administration reduces ASDS-induced stress priming to StSDS. Experimental timeline of the propranolol experiment on top. A Violin dot plot graph showing SI ratios in control (CTR) and defeated (DEF) groups following ASDS and StSDS in saline (SAL) and propranolol (PROP) treatment groups. Dashed line denotes the threshold for social avoidance (SI ratio = 1). B Bar graph of the absolute time animals spent in the interaction zone (IZ) during SIT after ASDS, showing no difference between groups when the CD1 target is not present (left panel) and in the presence of the CD1 target (right panel). C Bar graph of the time the animal spent exploring the IZ during SIT after StSDS in absence (left) and in presence (right) of the CD1 target. D Bar graph of the time the animal spent exploring the corners zone (CZ) during SIT after ASDS. E Bar graph of the time the animal spent exploring the CZ during SIT after StSDS. Data are presented as mean +/− SEM. Main effect ## P < 0.001, ### P < 0.0001. Post-hoc: *P < 0.05, **P < 0.01, *** P < 0.001. Using a repeated mixed-effect model to evaluate SI ratios across time (ASDS vs StSDS) and treatment groups (SAL_CTR, SAL_DEF, PROP_CTR, PROP_DEF), we looked at the effect of ASDS and treatment (SAL_vs_PROP) on SI ratios. We found a significant main effect of behavior (CTR_vs_DEF) on the SI ratios (F3,57 = 10.15, p < 0.0001), and a significant interaction between SI ratios across time and treatment (F3,55 = 3.039, p = 0.0366). Consistent with previous ASDS results, multiple comparison analysis revealed that saline treated defeated animals had significantly decreased SI ratio compared to controls (SAL_CTRASDS_vs_SAL_DEFASDS, p = 0.0042) (Fig. 2A). Similarly, propranolol defeated animals showed significantly decreased SI ratio compared to controls (PROP_CTRASDS_vs_PROP_DEFASDS, p = 0.0002) (Fig. 2A). These data prove that the ASDS paradigm induced robust social avoidance in all defeated animals irrespective of treatment. We next examined the effects of propranolol treatment on ASDS-induced stress-priming to subsequent StSDS. We confirmed that saline animals with a history of ASDS showed the stress-priming effect in the subsequent StSDS (SAL_CTRStSDS_vs_SAL_DEFStSDS, p = 0.0261) (Fig. 2A). However, after StSDS no differences emerged between ASDS control and defeated animals in the propranolol-treated groups (PROP_CTRStSDS_vs _PROP_DEFStSDS, p = 0.6846), indicating that propranolol blunted the susceptibility-priming effect of ASDS (Fig. 2A). On the contrary, the decreased SI ratios observed during ASDS (PROP_DEFASDS) amounting to 0.55 was completely rescued in the propranolol defeated (PROP_DEFStSDS) amounting to 0.86 during StSDS (p = 0.0262). We further looked at the effects of ASDS on the temporal dynamics of SI behavior by examining the time spent in the interaction zone (Fig. 2B & C) and the corners zone (Fig. 2D & E) with or without the novel CD-1 mouse target. No effect of ASDS or treatment was seen on interaction zone and corners zone times in the NO-target phase. We found a significant main effect of ASDS both in the interaction zone time (F1,57 = 27.87, p < 0.0001) and the corners zone time (F1,57 = 11.85, p = 0.0011) but no main effect of propranolol treatment nor interaction when the target was present. Post-hoc analysis showed that defeated animals spent significantly less time in the interaction zone both in CTR_DEF (p = 0.0051) and PROP_DEF (p = 0.0001), as opposed to significant more time in the corners zone only in the PROP_DEF group (p = 0.0181). These results demonstrate that propranolol injection before ASDS does not affect ASDS-induced social avoidance observed one-hour post-defeat. Similarly, we looked at how StSDS impacts primed and unprimed dynamics of SIT behavior by examining the time spent in the interaction zone (Fig. 2F & G) and the corners zone (Fig. 2H & I) with or without the novel CD-1 mouse target. No effect of StSDS or treatment was seen on zone occupancies times in the NO-target phase. We found a significant main effect of StSDS both in the interaction zone time (F1,55 = 11.62, p = 0.0012) and the corners zone time (F1,55 = 11.00, p = 0.0016) but no main effect of propranolol treatment nor interaction when the target was present. Post-hoc analysis showed that only CTR_DEF animals spent significantly less time in the interaction zone (p = 0.0041), but no difference was observed in the PROP_DEF group. This confirms that defeated animals display significant changes in basic movement or zone occupancy patterns during both ASDS and subsequent StSDS, supporting this stress priming effect, which was blunted by propranolol. An increased number of “freezer” animals observed in the propranolol-treated defeat group (Table S1 & Supplementary Fig. 1), might suggest that propranolol amplifies freezing selectively in the context of recent social stress, as an adaptive response to the recent social stressor. Still, these differences in zone occupancy were specific to social approach and avoidant behavior, and not reflecting any effect on locomotion, as confirmed by the lack of propranolol effects on locomotion and anxiety-like behavior in an open field test conducted in a separate cohort of mice (Figure S2A,B,C). We also tested propranolol effect on StSDS, shifting the injection of the blocker two minutes after ASDS, before SIT (Figure S2D). There was no effect of propranolol on the susceptibility priming, as shown by the post-hoc analysis on SI ratios of PROP_DEFASDS versus PROP_DEFStSDS groups (post-hoc: p = 0.7469). Corticosterone blocks acute ASDS-induced social avoidance but not susceptibility-priming to StSDS In the second experiment, we evaluated whether different doses of corticosterone, low, medium and high, injected 30 min before ASDS blocked the susceptibility-priming to subsequent StSDS (Fig. 3A). Two-way repeated-measures ANOVA conducted to evaluate SI ratios across time (ASDS vs StSDS) and corticosterone dose (LOW, MED, HI), revealed a strong main effect of the timepoint on SI ratio (F1,34 = 29.87, p < 0.0001), indicating that animals tested after StSDS exhibited significantly lower SI ratios than during ASDS across conditions. In contrast, there was no main effect of corticosterone dose (F2,54 = 1.264, p = 0.3021) and no significant interaction overall between timepoint and dose (F2,54 = 0.9976, p = 0.4340). Still, the multiple comparisons analysis revealed that mice receiving MED dose of CORT showed lower SI ratios following StSDS (MED_DEFASDS_vs_MED_DEFStSDS, p = 0.0020). Similarly, ASDS control mice treated with HI-CORT exhibited lower SI ratios following StSDS (HI_CTRASDS_vs_HI_CTRStSDS, p = 0.0006). These results demonstrate that corticosterone treatment at any dose did not reduce susceptibility-priming as hypothesized. Notably, we did not observe significant differences in SI ratios after ASDS between control and defeated mice at any corticosterone dose, in contrast to the standard ASDS-induced social avoidance in male mice (Fig. 3A). This suggests that corticosterone injections blunted the expression of social avoidance after social acute stress. This effect was apparent at low, medium, and high doses, with no corticosterone condition showing defeat-induced reduction in SI ratio after ASDS. Corticosterone administration interferes with ASDS social avoidance. Experimental timeline of the corticosterone experiment on top. A Violin dot plot graph showing SI ratios in control (CTR) and defeated (DEF) groups following ASDS and StSDS in the three mice groups injected, low dose (LOW CORT), medium dose (MED CORT) and high dose (HI CORT) of corticosterone. Dashed line denotes the threshold for social avoidance (SI ratio = 1). B Bar graph of the absolute time animals spent in the interaction zone (IZ) during SIT following ASDS, in the no target and target sessions. C Bar graph of the absolute time animals spent in IZ during SIT after StSDS without the CD1 target (left panel) and in the presence of the CD1 target (right panel). D Bar graph of the time the animals spent exploring the corners zone (CZ) during SIT after ASDS, in the no target and target sessions. E Bar graph of the time the animal spent exploring the CZ during SIT following StSDS without CD1 target and with CD1 target. Data are presented as mean +/− SEM. Main effect # P < 0.05, ## P < 0.001. Post-hoc: *P < 0.05, **P < 0.01, ***P < 0.001. To evaluate the behavioral patterns observed during SIT following ASDS, we looked at the absolute time spent in the different zones of the arena during the no target and target trials. Two-way repeated-measures ANOVA detected an overall stress effect during ASDS on absolute time in the interaction zone (F1,34 = 5.718, p = 0.0225), and absolute time in the corners zone (F1,34 = 21.11, p < 0.0001) in presence of the CD1 target mouse (respectively, Fig. 3C & E). Only for the HI dose, the multiple comparison analysis revealed a significant reduction in IZ time (F1,34 = 5.718, p = 0.0225), and a significant increase in CZ time (F1,34 = 21.11, p < 0.0001) in presence of the CD1 target mouse (Fig. 3C & E). Because these effects were main effects of defeat, they were observed across all corticosterone conditions and were not altered by drug treatment. This indicate that ASDS still induced detectable patterns of social avoidance, even though not represented in the SI ratios. Corticosterone injections disrupt the normal serum corticosterone response to ASDS In a separate mouse cohort, we evaluated how CORT serum levels change over time in response to CORT injection, sampling the levels before and after CORT injection, ASDS, and SIT. First, we evaluated the behavioral patterns observed during SIT following ASDS of the animals that underwent multiple tail blood collections. We looked at the absolute time spent in the different zones of the arena during the no target and target trials. Mixed-effects model analysis detected an overall stress effect during ASDS on absolute time in the interaction zone (F1,10 = 52.55, p < 0.0001), an effect of time in the interaction zone (F1,10 = 18.02, p = 0.0017), and a time x stress interaction (F1,2 = 74.81, p = 0.0131) in presence of the CD1 target mouse (Fig. 4A–C). Post-hoc analysis confirmed that defeated groups spent less time in the interaction zone: MED_CTR_vs_MED_DEF, p = 0.0097 and VEH_CTR_vs_VEH_DEF, p = 0.028 (Fig. 4A). Analysis of the time in the corners zone did not reveal any difference between groups (Fig. 4B). Analysis of the SI ratio showed a main effect of ASDS (F1,16 = 6.836, p = 0.018). Post-hoc analysis revealed that the SI ratio was significantly lower only in the CORT injected group (MED_CTR_vs_MED_DEF, p = 0.0285) (Fig. 4C). This suggests that MED CORT injections do not affect social avoidance after ASDS. The analysis of CORT serum levels at different time points (Fig. 4D), revealed a significant effect of time (F2.4,37.7 = 25.2, p < 0.0001) and a significant time x stress interaction (F7.3,37.7 = 3.5, p = 0.004). Post-hoc analysis revealed that 2-days prior to ASDS baseline, the MED_CTR group had higher corticosterone level compared to the VEH_DEF group (p = 0.008), however this difference normalized to all the other groups one day prior to ASDS. On the day of the ASDS, all groups showed higher levels of CORT at 15-min compared to the day prior to ASDS (baseline): VEH_CTR (p = 0.02), MED_CTR (p = 0.05), VEH_DEF (p = 0.004), MED_DEF (p = 0.0002). When comparing groups at the 15-min timepoint, the VEH_DEF (µ = 398.8) group had significantly higher CORT levels compared to the VEH_CTR (µ = 186.7, p = 0.03) and the MED_CTR (µ = 160.5, p = 0.03), but only a trend to the MED_DEF (µ = 215, p = 0.05). At 65-min, CORT levels dropped significantly in the defeated groups (VEH_DEF, p = 0.01 and MED_DEF, p = 0.002), compared to the 15-min peak observed, whereas the CTR groups maintained lower but sustained levels of CORT across time points. These data suggests that the peak of CORT appears 15-min after ASDS, and CORT injection 30-min prior ASDS blunts this peak in the CORT_DEF group. Controls injected with VEH showed a lower peak than the correspondent defeated group, also shifted towards the 30-min timepoints. MED CORT injections also reduce the CORT response in CTR at this 30-min timepoint. In a separate group of mice, we evaluated whether the medium dose of corticosterone injected two minutes after ASDS blocked the susceptibility-priming to subsequent StSDS (Fig. 4E). We conducted mixed-effects model analysis to evaluate SI ratios across time (ASDS_vs_StSDS) and treatment (CORT_vs_VEH). This revealed a strong main effect of the timepoint on SI ratio (F3,14 = 19.48, p = 0.0006), indicating that animals tested after StSDS exhibited significantly lower SI ratios than during ASDS across conditions. We also found a main effect of corticosterone (F3,14 = 4.302, p = 0.023). The effect of CORT after ASDS on StSDS showed that SI ratios were significantly lower in the MED_DEFStSDS (p = 0.01) and in the VEH_CTRStSDS (p = 0.007) compared to MED_DEFASDS, and VEH_CTRASDS respectively. Similarly to the results shown on CORT injection 30-min prior to ASDS, corticosterone treatment after ASDS did not reduce susceptibility-priming (Fig. 4E). Discussion The susceptibility priming effect is a phenomenon by which an animal exposed to an acute stressor is predisposed towards greater susceptibility following exposure to a subsequent stressor. This priming effect occurs even when the second stressor is mild and does not induce significant susceptibility in animals under normal conditions. Our interest lies in the initial response and neuro-circuitry underlying individual variation in stress responses, thus we investigated the effect of propranolol and corticosterone on the susceptibility-priming induced by acute stressor as two promising therapeutic compounds for the treatment of PTSD. Here, we investigated the capacity of a single acute administration of either propranolol, or corticosterone, to inhibit the susceptibility priming effect. We previously reported that ASDS in adult mice is sufficient to induce susceptibility to a mild stressor, such as StSDS [23]. We confirmed this phenotype by showing that the saline group, which experienced ASDS defeat, exhibited increase social avoidance, as indicated by reduced SI scores, decreased total time spent in the interaction zone and increased total time spent in corners zone in presence of the CD1. Consistent with the ASDS paradigm, defeated animals displayed lower SI ratios than control animals, in both saline and propranolol groups. This suggests that administration of propranolol had no effect on the initial ASDS, making it an optimal compound candidate to mitigate the neuro-circuitry changes associated with susceptibility priming after the initial stress response has occurred. Interestingly, we showed that social avoidance post-StSDS is reduced by propranolol injection 30 min prior to the onset of ASDS, which resulted in significant mitigation of susceptibility-priming. Our data demonstrated that propranolol administration prevented animals from developing further social susceptibility-priming to StSDS, as indicated by no significant differences in the time spent in the interaction and corners zones with or without the CD-1 mouse in the propranolol group. Our results are consistent with multiple lines of evidence showing that propranolol reduces stress-related behavioral responses. In chronic social defeat, chronic unpredictable stress, and restraint stress models, systemic propranolol attenuates anxiety-like and anhedonia-like behaviors, normalizes stress-induced hyperarousal, and mitigates neuroinflammatory and noradrenergic adaptations linked to susceptibility [25–27]. In several memory-related paradigms, propranolol can reverse previous effects of β-adrenoceptor agonism on post-training consolidation both if administered before or shortly after stress exposure therefore disrupting consolidation of aversive associations, reliably impairing fear memory reactivation, resulting in diminished freezing and reduced amygdala-dependent fear expression [15, 28]. Beyond amygdala circuits, recent work indicates that propranolol also modulates hippocampal network activity during fear retrieval, suggesting broader effects on mnemonic processes that contribute to stress-related memory expression [29, 30]. Consistent with prior work, propranolol effectively mitigates fear-related freezing and weakens reconsolidation of aversive memories in classical fear-conditioning paradigms (e.g., tone or contextual fear conditioning) [31–34]. Zaida et al. [25] showed that a prophylactic effect of propranolol prevented social defeat–induced anxiety and restored social interaction in chronic social defeat model, where rats received propranolol for 36 days pre-defeat. Unlike prior studies which focused on passive fear responses, both studies highlight the social component of stress susceptibility, namely social avoidance and social exploration. Our study is the first to examine the role of propranolol on social memory in acute treatment, showing that propranolol can prevent the priming of social susceptibility following a subsequent mild stress when administered before the first stressor but not soon after. Thus, prophylactic β-adrenergic blockades appear to mitigate susceptibility priming and prevent the emergence of a social-avoidant phenotype after re-exposure to mild social challenge, possibly by inhibiting noradrenergic-dependent emotional encoding that is needed for long-term consolidation of social memory leading to blockade of priming but not affecting the recall of defeat experience on a short-time scale. Several key questions remain. In our study, we looked only at males, and the literature on sex differences are limited. In addition, multiple dose parameters in acute and chronic stress paradigms should be tested. Addressing these issues through validated animal models is essential for reducing the current translational gap of propranolol use in clinical trials. Contrary to propranolol, corticosterone administered prior to or soon after ASDS failed to prevent susceptibility priming and, at medium and high doses, appeared to enhance susceptibility-priming to subsequent social stress, as evidenced by significant SI ratio decrease in both MED_DEF and HI_CTR groups between time-points. This lack of efficacy may reflect a disruption of the precise temporal coordination between HPA-axis activation and noradrenergic signaling required for adaptive memory modulation. It has been shown that higher stress-induced glucocorticoid serum levels enhance stress-related memories [26–28]. According to the memory modulation framework [35], glucocorticoids enhance the consolidation of emotionally salient experiences only when coupled with concurrent β-adrenergic activation within the basolateral amygdala; thus, exogenous corticosterone administered around ASDS may have uncoupled this interaction, leading to maladaptive encoding of the stress experience. Consistent with this interpretation, corticosterone pre-ASDS also altered the acute behavioral response to ASDS, as the paradigm normally would induce a clear distinction between the mean SI scores of controls and defeated animals, whereas only mice in the high dose group spent significant less time in proximity of the CD-1 compared to the controls. This suggests that elevation of glucocorticoids around the stressor time might have engaged negative feedback mechanisms and shifted HPA-axis dynamics outside the optimal window for adaptive processing. According to Andrews et al. [36], an increase in glucocorticoid receptor (GR) activation leads to dose-dependent suppression of basal HPA axis activity in female rats. The effect lasts up to several hours but is subject to a finite dose-dependent delay, with the earliest suppression onset 40-min after low dose steroid injection. Accordingly, our data show how MED CORT prior ASDS induced a reduction of the serum CORT levels at 15-min in DEF groups and at 30-min in CTR groups, respectively 45 and 60-min after injection, though producing normal defeat responses in contrast to the priming experiment, possibly as an effect of the multiple tail-blood collection. Our data indicates that the onset of the HPA axis suppression preceded the SIT, possibly amplifying stress activation soon after defeat, while buffering the stress response during SIT testing. The high dose of 25 mg/kg of the steroid compound used here might have shifted the onset of the above suppression after SIT, resulting in disrupted social interaction pattern in the defeated group. Moreover, the dose-dependent effects observed here align with the well-established inverted-U relationship governing glucocorticoid actions, whereby excessive or prolonged receptor activation across dose and timing, particularly of glucocorticoid receptors (GRs), can impair cognitive and emotional regulation [37–41]. This effect, also known as hormesis, [42] is specific to the level of expression of mineralocorticoid receptors (MRs) and GRs in the brain areas sensitive to CORT levels, with the Paraventricular Nucleus of the Hypothalamus and Amygdala having stronger GR-driven excitability/plasticity changes than Hippocampus. Hence, it is plausible that the corticosterone administered around ASDS acted at a different time scale for each dose in activated brain areas, still producing a long-term effect on subsequent stressors. Thus, a medium or high dose of corticosterone was sufficient to prime animals towards a second stressor, as observed by a decreased SI ratio in the high corticosterone control group. In agreement with Jaszczyk et al. [43], acute-to-subacute CORT elevation can produce real but modest and selective effects with a broad time-course: some changes are rapid (within hours), others delayed and some persist after hormone returns to baseline. Together, these findings support a model in which corticosterone alone is insufficient to prevent susceptibility-priming and may instead exacerbate it when the balance and timing of interacting stress systems are disrupted. As for propranolol, future experiments should include females as most of the present studies for preclinical model on CORT protective effects have been performed mainly on males. Moreover, the reported CORT time-course in blood serum should include the high-dose group and could be conducted on fecal samples to remove the caveat of blood collection as possible minor stressor [44]. Future studies incorporating circadian elements into the design will be essential to determine how temporal fluctuations in glucocorticoid signaling influence susceptibility priming and stress-related outcomes. Overall, this study extends our knowledge of the impact of an initial stressful event on a future re-exposure to stressors, and it opens the possibility for acting on and interfering with this priming effect. Additionally, the promising effect of propranolol will allow us to compare its effects on the pre-existing and unmodified neurobiological mechanisms responsible for individual variability in the stress response. Supplementary information Supplementary Acknowledgements This research was supported by an R01MH111918 (DD). The authors declare no competing financial interests related to the work presented in this paper. Author contributions JYZ and DD conceptualized the study. JYZ CF AM and GZ collected the data. AM and GZ analyzed the data and visualized the findings. AM and GZ wrote the manuscript. All authors reviewed, edited, and approved the manuscript. DD provided oversight and supervision. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-026-04205-0. References Associated Data Supplementary Materials Supplementary